Add like
Add dislike
Add to saved papers

Characteristics and hormonal contraception use patterns of levonorgestrel 13.5 mg intrauterine device users in Sweden 2014-2016.

Contraception 2023 October 15
OBJECTIVE: The levonorgestrel-releasing intrauterine device containing 13.5 mg of levonorgestrel (LNG 13.5 mg IUD), Jaydess®, was approved for contraception by the European Medicines Agency in 2013. We aimed to describe the characteristics of new users of LNG 13.5 mg IUD in Sweden within the first 3 years after approval (2014-2016).

STUDY DESIGN: We conducted an observational, population-based study using data from the Swedish national registers. Women with a first pharmacy dispensation of LNG 13.5 mg IUD between 2014-2016 were followed until 31 December 2020. Descriptive analyses included demographic characteristics, duration of use of first-time LNG 13.5 mg IUD, and contraceptive switching patterns.

RESULTS: We included 38,327 women, with mean age at first-time LNG 13.5 mg IUD use of 26 (standard deviation: 7) years. Over 80% were prescribed LNG 13.5 mg IUD by a midwife. The most common comorbidities in the year prior to LNG 13.5 mg IUD use (2-3% prevalence) were depression, anxiety, premenstrual syndrome, and menorrhagia. The median duration of first-time LNG 13.5 mg IUD use was 2.6 years, and after use, more than 50% of women opted to continue using a hormonal intrauterine device.

CONCLUSIONS: In this post-marketing drug utilization study, there were over 38,000 first-time LNG 13.5 mg IUD users in Sweden between 2014-2016, with an estimated median duration of use of 2.6 years. First-time LNG 13.5 mg IUD users consisted mostly of young, healthy individuals with a history of hormonal contraceptive use. Over half of the women continued using a hormonal IUD after the first LNG 13.5 mg IUD.

IMPLICATIONS: The median duration of LNG 13.5 mg IUD use was 2.6 years, approaching the 3-year indicated use limit. The majority of users continued with another hormonal intrauterine device after LNG 13.5 mg IUD use.

TWEETABLE ABSTRACT: Drug utilization @karolinskainst study of >38,000 #women shows that most first-time users of #LNG 13.5 mg IUD are young, healthy women seeking contraception. Estimated median duration in line with approved labeling #womenshealth #contraception.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app